Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Beijing Tong Ren Tang Chinese Medicine Co ( (HK:3613) ) just unveiled an update.
Beijing Tong Ren Tang Chinese Medicine Company Limited announced its unaudited interim results for the first half of 2025. The report, which complies with the Stock Exchange of Hong Kong’s listing rules, will be available to shareholders and online by the end of September 2025. This announcement reflects the company’s ongoing commitment to transparency and regulatory compliance, potentially impacting its market position and stakeholder confidence.
The most recent analyst rating on (HK:3613) stock is a Buy with a HK$10.50 price target. To see the full list of analyst forecasts on Beijing Tong Ren Tang Chinese Medicine Co stock, see the HK:3613 Stock Forecast page.
More about Beijing Tong Ren Tang Chinese Medicine Co
Beijing Tong Ren Tang Chinese Medicine Company Limited operates in the traditional Chinese medicine industry, focusing on the production and distribution of Chinese medicinal products. The company is incorporated in Hong Kong and is listed on the Stock Exchange of Hong Kong.
Average Trading Volume: 1,247,064
Technical Sentiment Signal: Buy
Current Market Cap: HK$7.69B
Find detailed analytics on 3613 stock on TipRanks’ Stock Analysis page.